DE69105040T2 - Arzneimittel gegen Impotenz. - Google Patents

Arzneimittel gegen Impotenz.

Info

Publication number
DE69105040T2
DE69105040T2 DE69105040T DE69105040T DE69105040T2 DE 69105040 T2 DE69105040 T2 DE 69105040T2 DE 69105040 T DE69105040 T DE 69105040T DE 69105040 T DE69105040 T DE 69105040T DE 69105040 T2 DE69105040 T2 DE 69105040T2
Authority
DE
Germany
Prior art keywords
impotence
medicines
relieving
male
erectile impotence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69105040T
Other languages
English (en)
Other versions
DE69105040D1 (de
Inventor
George Mclean Milne
Michael Grant Wyllie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69105040D1 publication Critical patent/DE69105040D1/de
Publication of DE69105040T2 publication Critical patent/DE69105040T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
DE69105040T 1990-05-31 1991-05-17 Arzneimittel gegen Impotenz. Expired - Fee Related DE69105040T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53149490A 1990-05-31 1990-05-31

Publications (2)

Publication Number Publication Date
DE69105040D1 DE69105040D1 (de) 1994-12-15
DE69105040T2 true DE69105040T2 (de) 1995-03-23

Family

ID=24117862

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69105040T Expired - Fee Related DE69105040T2 (de) 1990-05-31 1991-05-17 Arzneimittel gegen Impotenz.

Country Status (15)

Country Link
EP (1) EP0459666B1 (de)
JP (1) JP2522609B2 (de)
KR (1) KR930010582B1 (de)
AT (1) ATE113839T1 (de)
AU (1) AU620282B2 (de)
CA (1) CA2043440C (de)
DE (1) DE69105040T2 (de)
DK (1) DK0459666T3 (de)
HU (1) HU208076B (de)
IE (1) IE63837B1 (de)
IL (1) IL98258A (de)
MY (1) MY106528A (de)
NZ (1) NZ238339A (de)
PT (1) PT97785B (de)
ZA (1) ZA914135B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4223800A1 (de) * 1992-07-20 1994-01-27 Cassella Farbwerke Mainkur Ag Verwendung von 1.2.5-Oxadiazol-2-oxiden zur Behandlung erektiler Dysfunktionen
ATE190843T1 (de) * 1993-02-10 2000-04-15 Bmra Corp Bv Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
HUT77941A (hu) * 1994-11-16 1998-12-28 Synaptic Pharmaceutical Corporation Dihidropirimidinszármazékok és ezek alkalmazása
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
CZ278497A3 (cs) * 1995-03-14 1998-04-15 Vivus, Incorporated Způsob a sestava zařízení k prevenci impotence
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
YU49898A (sh) * 1996-05-10 2000-03-21 Icos Corporation Hemijska jedinjenja
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
EP0849264A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von doxazosinmesylat (Form I)
DK0849266T3 (da) * 1996-12-20 2007-06-04 Heumann Pcs Gmbh Hidtil ukendt polymorf form af doxazosin-mesylat (form III)
CZ20002199A3 (cs) * 1997-12-16 2001-10-17 Pfizer Products Inc. Kombinace, kompozice a kity pro léčení impotence a samičí sexuální dysfunkce
DE19800214A1 (de) * 1998-01-06 1999-07-15 Knoll Ag Verfahren zur Herstellung von Doxazosin-Mcsylat in einer als Form A bezeichneten Kristallmodifikation und ein Zwischenprodukt dafür
US6268377B1 (en) * 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
RU2135195C1 (ru) * 1998-12-17 1999-08-27 Овсюк Валерий Григорьевич Способ получения материала, содержащего клетки предстательной железы, материал, содержащий клетки предстательной железы, и способы лечения фиброматоза матки, хронического простатита и нарушений мужской половой функции методом трансплантации
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
US6521647B2 (en) 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
JP2003532678A (ja) * 2000-05-12 2003-11-05 ノバラー ファーマシューティカルズ， インコーポレイテッド 局所麻酔の方法およびキット
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions

Also Published As

Publication number Publication date
HU208076B (en) 1993-08-30
IE911842A1 (en) 1991-12-04
EP0459666A2 (de) 1991-12-04
ZA914135B (en) 1993-01-27
IL98258A (en) 1996-01-31
MY106528A (en) 1995-06-30
HUT58520A (en) 1992-03-30
EP0459666A3 (en) 1992-06-03
DK0459666T3 (da) 1994-12-05
KR930010582B1 (ko) 1993-10-30
CA2043440A1 (en) 1991-12-01
JPH04235917A (ja) 1992-08-25
CA2043440C (en) 1996-07-30
KR910019618A (ko) 1991-12-19
EP0459666B1 (de) 1994-11-09
JP2522609B2 (ja) 1996-08-07
ATE113839T1 (de) 1994-11-15
PT97785A (pt) 1992-02-28
IL98258A0 (en) 1992-06-21
AU7807791A (en) 1991-12-05
HU911810D0 (en) 1991-12-30
AU620282B2 (en) 1992-02-13
NZ238339A (en) 1997-07-27
DE69105040D1 (de) 1994-12-15
IE63837B1 (en) 1995-06-14
PT97785B (pt) 1999-01-29

Similar Documents

Publication Publication Date Title
DE69105040D1 (de) Arzneimittel gegen Impotenz.
ATE145551T1 (de) Brausedosisform sowie verfahren zu deren verabreichung
ATE198835T1 (de) Knochenwachstumsfördernde zusammensetzung
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
DE69129800T2 (de) Behandlung von menschlichen retrovirus-infektionen mit 2',3'-dideoxyinosin
TW273550B (de)
DK0449247T3 (da) Farmaceutisk formulering indeholdende galanthamin til behandling af alkoholisme
NO922936D0 (no) Fremstilling av fettsyremedikamenter
PT615754E (pt) Formas solidas de administracao oral de libertacao controlada flupertina
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
DK0458588T3 (da) Behandling af okulær hypertension med en synergistisk kombination til okulær administration
FI945510A (fi) Klavulaanihapon diamiinisuolat
EP0362847A3 (de) Verwendung von Etoperidon zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von männlicher Impotenz
LU90791I2 (fr) Potentialisateur d'effets antineoplasique et agent antineoplasique
IT9086204A0 (it) Metodo per la cura dell'impotenza erettiva maschile
ITRM910550A0 (it) Preparazioni farmaceutiche orali, a base di acidi biliari, a cessione protratta e controllata con le quali e' possibile adottare una sola somministrazione giornaliera
EP0482919A3 (en) Method and composition for treating leg weakness in fowl by the administration of a non-steroidal anti-inflammatory drug
RU93044256A (ru) Способ лечения саркоидоза
RU93042104A (ru) Противокашлевая композиция, содержащая декстрометорфан, способ ее применения
ATE181828T1 (de) Oral anzuwendendes arzneimittel bestehend aus ibuprofen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee